COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry

L. Garrigos; C. Saura; C. Martinez-Vila; A. Zambelli; M. Bower; B. Pistilli; M. Lambertini; D. Ottaviani; N. Diamantis; A. Lumsden; S. Pernas; D. Generali; E. Segui; G. Vinas; E. Felip; A. Sanchez; G. Rizzo; A. Santoro; A. Cortellini; Y. Perone; J. Chester; M. Iglesias; M. Betti; B. Vincenzi; M. Libertini; F. Mazzoni; F. Zoratto; R. Berardi; A. Guida; R. Wuerstlein; A. Loizidou; R. Sharkey; Company J. Aguilar; M. Matas; C. Saggia; L. Chiudinelli; E. Colomba-Blameble; M. Galazi; U. Mukherjee; Hemelrijck M. Van; M. Marin; C. Strina; A. Prat; H. Pla; E. M. Ciruelos; A. Bertuzzi; Mastro L. del; G. Porzio; T. Newsom-Davis; I. Ruiz; M. B. Delany; Marco KRENGLI; V. Fotia; A. Viansone; N. Chopra; M. Romeo; R. Salazar; I. Perez; F. d'Avanzo; M. Franchi; M. Milani; F. Pommeret; M. Tucci; P. Pedrazzoli; N. Harbeck; Daniela FERRANTE; David James PINATO; Alessandra Gennari

doi:10.1177/17588359211053416

COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry

L. Garrigos, C. Saura, C. Martinez-Vila, A. Zambelli, M. Bower, B. Pistilli, M. Lambertini, D. Ottaviani, N. Diamantis, A. Lumsden, S. Pernas, D. Generali, E. Segui, G. Vinas, E. Felip, A. Sanchez, G. Rizzo, A. Santoro, A. Cortellini, Y. PeroneJ. Chester, M. Iglesias, M. Betti, B. Vincenzi, M. Libertini, F. Mazzoni, F. Zoratto, R. Berardi, A. Guida, R. Wuerstlein, A. Loizidou, R. Sharkey, Company J. Aguilar, M. Matas, C. Saggia, L. Chiudinelli, E. Colomba-Blameble, M. Galazi, U. Mukherjee, Hemelrijck M. Van, M. Marin, C. Strina, A. Prat, H. Pla, E. M. Ciruelos, A. Bertuzzi, Mastro L. del, G. Porzio, T. Newsom-Davis, I. Ruiz, M. B. Delany, Marco KRENGLI, V. Fotia, A. Viansone, N. Chopra, M. Romeo, R. Salazar, I. Perez, F. d'Avanzo, M. Franchi, M. Milani, F. Pommeret, M. Tucci, P. Pedrazzoli, N. Harbeck, Daniela FERRANTE, David James PINATO, Alessandra Gennari

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

Background: Cancer patients are at higher risk of COVID-19 complications and mortality than the rest of the population. Breast cancer patients seem to have better prognosis when infected by SARS-CoV-2 than other cancer patients. Methods: We report a subanalysis of the OnCovid study providing more detailed information in the breast cancer population. Results: We included 495 breast cancer patients with a SARS-CoV-2 infection. Mean age was 62.6 years; 31.5% presented more than one comorbidity. The most frequent breast cancer subtype was luminal-like (n = 245, 49.5%) and 177 (35.8%) had metastatic disease. A total of 332 (67.1%) patients were receiving active treatment, with radical intent in 232 (47.6%) of them. Hospitalization rate was 58.2% and all-cause mortality rate was 20.3%. One hundred twenty-nine (26.1%) patients developed one COVID-19 complication, being acute respiratory failure the most common (n = 74, 15.0%). In the multivariable analysis, age older than 70 years, presence of COVID-19 complications, and metastatic disease were factors correlated with worse outcomes, while ongoing anticancer therapy at time of COVID-19 diagnosis appeared to be a protective factor. No particular oncological treatment was related to higher risk of complications. In the context of SARS-CoV-2 infection, 73 (18.3%) patients had some kind of modification on their oncologic treatment. At the first oncological reassessment (median time: 46.9 days ± 36.7), 255 (51.6%) patients reported to be fully recovered from the infection. There were 39 patients (7.9%) with long-term SARS-CoV-2-related complications. Conclusion: In the context of COVID-19, our data confirm that breast cancer patients appear to have lower complications and mortality rate than expected in other cancer populations. Most breast cancer patients can be safely treated for their neoplasm during SARS-CoV-2 pandemic. Oncological treatment has no impact on the risk of SARS-CoV-2 complications, and, especially in the curative setting, the treatment should be modified as little as possible.

Lingua originale	Inglese
pagine (da-a)	17588359211053416
Rivista	Therapeutic Advances in Medical Oncology
Volume	13
DOI	https://doi.org/10.1177/17588359211053416
Stato di pubblicazione	Pubblicato - 2021

Keywords

breast cancer
COVID-19
COVID-19 outcomes
OnCovid
SARS-CoV-2

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1177/17588359211053416

https://hdl.handle.net/11579/159416

Altri file e collegamenti

handle

Cita questo

Garrigos, L., Saura, C., Martinez-Vila, C., Zambelli, A., Bower, M., Pistilli, B., Lambertini, M., Ottaviani, D., Diamantis, N., Lumsden, A., Pernas, S., Generali, D., Segui, E., Vinas, G., Felip, E., Sanchez, A., Rizzo, G., Santoro, A., Cortellini, A., ... Gennari, A. (2021). COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. Therapeutic Advances in Medical Oncology, 13, 17588359211053416. https://doi.org/10.1177/17588359211053416

@article{da87ffb677734df49b40636b4f78424d,

title = "COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry",

abstract = "Background: Cancer patients are at higher risk of COVID-19 complications and mortality than the rest of the population. Breast cancer patients seem to have better prognosis when infected by SARS-CoV-2 than other cancer patients. Methods: We report a subanalysis of the OnCovid study providing more detailed information in the breast cancer population. Results: We included 495 breast cancer patients with a SARS-CoV-2 infection. Mean age was 62.6 years; 31.5\% presented more than one comorbidity. The most frequent breast cancer subtype was luminal-like (n = 245, 49.5\%) and 177 (35.8\%) had metastatic disease. A total of 332 (67.1\%) patients were receiving active treatment, with radical intent in 232 (47.6\%) of them. Hospitalization rate was 58.2\% and all-cause mortality rate was 20.3\%. One hundred twenty-nine (26.1\%) patients developed one COVID-19 complication, being acute respiratory failure the most common (n = 74, 15.0\%). In the multivariable analysis, age older than 70 years, presence of COVID-19 complications, and metastatic disease were factors correlated with worse outcomes, while ongoing anticancer therapy at time of COVID-19 diagnosis appeared to be a protective factor. No particular oncological treatment was related to higher risk of complications. In the context of SARS-CoV-2 infection, 73 (18.3\%) patients had some kind of modification on their oncologic treatment. At the first oncological reassessment (median time: 46.9 days ± 36.7), 255 (51.6\%) patients reported to be fully recovered from the infection. There were 39 patients (7.9\%) with long-term SARS-CoV-2-related complications. Conclusion: In the context of COVID-19, our data confirm that breast cancer patients appear to have lower complications and mortality rate than expected in other cancer populations. Most breast cancer patients can be safely treated for their neoplasm during SARS-CoV-2 pandemic. Oncological treatment has no impact on the risk of SARS-CoV-2 complications, and, especially in the curative setting, the treatment should be modified as little as possible.",

keywords = "breast cancer, COVID-19, COVID-19 outcomes, OnCovid, SARS-CoV-2, breast cancer, COVID-19, COVID-19 outcomes, OnCovid, SARS-CoV-2",

author = "L. Garrigos and C. Saura and C. Martinez-Vila and A. Zambelli and M. Bower and B. Pistilli and M. Lambertini and D. Ottaviani and N. Diamantis and A. Lumsden and S. Pernas and D. Generali and E. Segui and G. Vinas and E. Felip and A. Sanchez and G. Rizzo and A. Santoro and A. Cortellini and Y. Perone and J. Chester and M. Iglesias and M. Betti and B. Vincenzi and M. Libertini and F. Mazzoni and F. Zoratto and R. Berardi and A. Guida and R. Wuerstlein and A. Loizidou and R. Sharkey and Aguilar, \{Company J.\} and M. Matas and C. Saggia and L. Chiudinelli and E. Colomba-Blameble and M. Galazi and U. Mukherjee and Van, \{Hemelrijck M.\} and M. Marin and C. Strina and A. Prat and H. Pla and Ciruelos, \{E. M.\} and A. Bertuzzi and del, \{Mastro L.\} and G. Porzio and T. Newsom-Davis and I. Ruiz and Delany, \{M. B.\} and Marco KRENGLI and V. Fotia and A. Viansone and N. Chopra and M. Romeo and R. Salazar and I. Perez and F. d'Avanzo and M. Franchi and M. Milani and F. Pommeret and M. Tucci and P. Pedrazzoli and N. Harbeck and Daniela FERRANTE and PINATO, \{David James\} and Alessandra Gennari",

year = "2021",

doi = "10.1177/17588359211053416",

language = "English",

volume = "13",

pages = "17588359211053416",

journal = "Therapeutic Advances in Medical Oncology",

issn = "1758-8340",

publisher = "SAGE Publications Inc.",

}

Garrigos, L, Saura, C, Martinez-Vila, C, Zambelli, A, Bower, M, Pistilli, B, Lambertini, M, Ottaviani, D, Diamantis, N, Lumsden, A, Pernas, S, Generali, D, Segui, E, Vinas, G, Felip, E, Sanchez, A, Rizzo, G, Santoro, A, Cortellini, A, Perone, Y, Chester, J, Iglesias, M, Betti, M, Vincenzi, B, Libertini, M, Mazzoni, F, Zoratto, F, Berardi, R, Guida, A, Wuerstlein, R, Loizidou, A, Sharkey, R, Aguilar, CJ, Matas, M, Saggia, C, Chiudinelli, L, Colomba-Blameble, E, Galazi, M, Mukherjee, U, Van, HM, Marin, M, Strina, C, Prat, A, Pla, H, Ciruelos, EM, Bertuzzi, A, del, ML, Porzio, G, Newsom-Davis, T, Ruiz, I, Delany, MB, KRENGLI, M, Fotia, V, Viansone, A, Chopra, N, Romeo, M, Salazar, R, Perez, I, d'Avanzo, F, Franchi, M, Milani, M, Pommeret, F, Tucci, M, Pedrazzoli, P, Harbeck, N, FERRANTE, D , PINATO, DJ & Gennari, A 2021, 'COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry', Therapeutic Advances in Medical Oncology, vol. 13, pagg. 17588359211053416. https://doi.org/10.1177/17588359211053416

TY - JOUR

T1 - COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry

AU - Garrigos, L.

AU - Saura, C.

AU - Martinez-Vila, C.

AU - Zambelli, A.

AU - Bower, M.

AU - Pistilli, B.

AU - Lambertini, M.

AU - Ottaviani, D.

AU - Diamantis, N.

AU - Lumsden, A.

AU - Pernas, S.

AU - Generali, D.

AU - Segui, E.

AU - Vinas, G.

AU - Felip, E.

AU - Sanchez, A.

AU - Rizzo, G.

AU - Santoro, A.

AU - Cortellini, A.

AU - Perone, Y.

AU - Chester, J.

AU - Iglesias, M.

AU - Betti, M.

AU - Vincenzi, B.

AU - Libertini, M.

AU - Mazzoni, F.

AU - Zoratto, F.

AU - Berardi, R.

AU - Guida, A.

AU - Wuerstlein, R.

AU - Loizidou, A.

AU - Sharkey, R.

AU - Aguilar, Company J.

AU - Matas, M.

AU - Saggia, C.

AU - Chiudinelli, L.

AU - Colomba-Blameble, E.

AU - Galazi, M.

AU - Mukherjee, U.

AU - Van, Hemelrijck M.

AU - Marin, M.

AU - Strina, C.

AU - Prat, A.

AU - Pla, H.

AU - Ciruelos, E. M.

AU - Bertuzzi, A.

AU - del, Mastro L.

AU - Porzio, G.

AU - Newsom-Davis, T.

AU - Ruiz, I.

AU - Delany, M. B.

AU - KRENGLI, Marco

AU - Fotia, V.

AU - Viansone, A.

AU - Chopra, N.

AU - Romeo, M.

AU - Salazar, R.

AU - Perez, I.

AU - d'Avanzo, F.

AU - Franchi, M.

AU - Milani, M.

AU - Pommeret, F.

AU - Tucci, M.

AU - Pedrazzoli, P.

AU - Harbeck, N.

AU - FERRANTE, Daniela

AU - PINATO, David James

AU - Gennari, Alessandra

PY - 2021

Y1 - 2021

N2 - Background: Cancer patients are at higher risk of COVID-19 complications and mortality than the rest of the population. Breast cancer patients seem to have better prognosis when infected by SARS-CoV-2 than other cancer patients. Methods: We report a subanalysis of the OnCovid study providing more detailed information in the breast cancer population. Results: We included 495 breast cancer patients with a SARS-CoV-2 infection. Mean age was 62.6 years; 31.5% presented more than one comorbidity. The most frequent breast cancer subtype was luminal-like (n = 245, 49.5%) and 177 (35.8%) had metastatic disease. A total of 332 (67.1%) patients were receiving active treatment, with radical intent in 232 (47.6%) of them. Hospitalization rate was 58.2% and all-cause mortality rate was 20.3%. One hundred twenty-nine (26.1%) patients developed one COVID-19 complication, being acute respiratory failure the most common (n = 74, 15.0%). In the multivariable analysis, age older than 70 years, presence of COVID-19 complications, and metastatic disease were factors correlated with worse outcomes, while ongoing anticancer therapy at time of COVID-19 diagnosis appeared to be a protective factor. No particular oncological treatment was related to higher risk of complications. In the context of SARS-CoV-2 infection, 73 (18.3%) patients had some kind of modification on their oncologic treatment. At the first oncological reassessment (median time: 46.9 days ± 36.7), 255 (51.6%) patients reported to be fully recovered from the infection. There were 39 patients (7.9%) with long-term SARS-CoV-2-related complications. Conclusion: In the context of COVID-19, our data confirm that breast cancer patients appear to have lower complications and mortality rate than expected in other cancer populations. Most breast cancer patients can be safely treated for their neoplasm during SARS-CoV-2 pandemic. Oncological treatment has no impact on the risk of SARS-CoV-2 complications, and, especially in the curative setting, the treatment should be modified as little as possible.

AB - Background: Cancer patients are at higher risk of COVID-19 complications and mortality than the rest of the population. Breast cancer patients seem to have better prognosis when infected by SARS-CoV-2 than other cancer patients. Methods: We report a subanalysis of the OnCovid study providing more detailed information in the breast cancer population. Results: We included 495 breast cancer patients with a SARS-CoV-2 infection. Mean age was 62.6 years; 31.5% presented more than one comorbidity. The most frequent breast cancer subtype was luminal-like (n = 245, 49.5%) and 177 (35.8%) had metastatic disease. A total of 332 (67.1%) patients were receiving active treatment, with radical intent in 232 (47.6%) of them. Hospitalization rate was 58.2% and all-cause mortality rate was 20.3%. One hundred twenty-nine (26.1%) patients developed one COVID-19 complication, being acute respiratory failure the most common (n = 74, 15.0%). In the multivariable analysis, age older than 70 years, presence of COVID-19 complications, and metastatic disease were factors correlated with worse outcomes, while ongoing anticancer therapy at time of COVID-19 diagnosis appeared to be a protective factor. No particular oncological treatment was related to higher risk of complications. In the context of SARS-CoV-2 infection, 73 (18.3%) patients had some kind of modification on their oncologic treatment. At the first oncological reassessment (median time: 46.9 days ± 36.7), 255 (51.6%) patients reported to be fully recovered from the infection. There were 39 patients (7.9%) with long-term SARS-CoV-2-related complications. Conclusion: In the context of COVID-19, our data confirm that breast cancer patients appear to have lower complications and mortality rate than expected in other cancer populations. Most breast cancer patients can be safely treated for their neoplasm during SARS-CoV-2 pandemic. Oncological treatment has no impact on the risk of SARS-CoV-2 complications, and, especially in the curative setting, the treatment should be modified as little as possible.

KW - breast cancer

KW - COVID-19

KW - COVID-19 outcomes

KW - OnCovid

KW - SARS-CoV-2

KW - breast cancer

KW - COVID-19

KW - COVID-19 outcomes

KW - OnCovid

KW - SARS-CoV-2

UR - https://iris.uniupo.it/handle/11579/159416

U2 - 10.1177/17588359211053416

DO - 10.1177/17588359211053416

M3 - Article

SN - 1758-8340

VL - 13

SP - 17588359211053416

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

ER -

COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo